A comparison of chronaxies for ventricular fibrillation induction, defibrillation, and cardiac stimulation: unexpected findings and their implications

INTRODUCTION

A low-energy (<or= 4 J) cardioversion shock (LEC) either terminates reentrant ventricular tachycardia (VT) or accelerates it to ventricular fibrillation (VF). Optimization of the duration and amplitude of LEC shocks could improve the success rate of VT termination without VF induction.

METHODS AND RESULTS

In order to learn how LEC shocks may be optimized, we used an animal model to compare the strength-duration curve for VF induction and the strength-duration curve for cardiac stimulation via the shock coil. Conventional implantable cardioverter-defibrillator (ICD) leads were implanted in 12 narcotized pigs from 20 kg to 25 kg in weight. Stimulation, VF induction, and defibrillation pulses were delivered by custom-designed stimulators at preset pulse durations and amplitudes. The corresponding hyperbolic strength-duration curves were constructed using the least-squares fit method and averaged for all the animals. The mean chronaxie for stimulation via the shock coil of 0.23 ms was significantly shorter than both defibrillation (4.8 ms) and VF induction (3.1 ms) chronaxie values. At a shock duration of 0.3 ms or less, the mean VF-induction threshold amplitude exceeded 300 V.

CONCLUSION

It may be reasonable to study whether LEC pulses from 0.25 ms to 0.30 ms in duration and up to 250 V in amplitude would increase therapeutic yield in VT termination without VF induction in humans. Contrary to the current belief, the discrepancy between defibrillation and stimulation chronaxie is not caused by different electrode size. We postulate that the time constant of the fast sodium channel reactivation may be the underlying reason.

Optimization of the neck region of dental implants with a bioactive, resorbable coating

With the goal of shortening the postoperative healing phase and the minimization of the risk of peri-implantitis around dental implants, a polymer coating, with improved surface biocompatibility in the region of soft tissue penetration by the implant, was investigated. The polymer used was the relatively slowly resorbable poly-beta-hydroxybuterate (PHB) whose surface was further activated in a NH3--plasma. The influence of surface roughness of the substrate (commercially pure titanium) as well as the influence of the edge radii on the test samples was determined in prior studies. These studies formed the basis for an optimised coating process. In-vitro biocompatibility was determined using a human gingival primary cell culture. Surface morphology was determined with SEM and AFM to complement the cell culture studies.